Autopsy report · NCT04171765
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
Cause of deathFunding or business
“The study was terminated due to strategic business reasons.”
Life of this trial
- Registered 10 months before it started.
- Ran for about 2 years 4 months before it stopped.
- 46 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Genentech, Inc.
- Sponsor type
- Industry
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Placebo; BFKB8488A
- Participants
- 46
- Sites
- 53
- Countries
- Belgium, France, Puerto Rico, Spain, United States
Trials that died the same way
- TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
“Study terminated for strategic business reasons” - Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
“The study was terminated due to a business decision.” - Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
“Study terminated due to business and strategic decision.” - Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma
“The study was terminated from a business perspective.” - A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
“Study terminated as part of strategic considerations”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.